#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	2700	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2184	359.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1451	1451	C	389	C,G	325,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	2700	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2184	359.7	0	HET	.	.	.	A37T	.	37	37	A	304	304	A	399	A,T	256,85	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4386	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3954	331.7	0	.	n	.	0	T695C	SNP	695	695	T	1217	1217	C	316	C	269	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4386	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3954	331.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1859	1859	A	409	A	343	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4386	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3954	331.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2493	2493	C	441	C	366	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4386	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3954	331.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3119	3119	T	346	T	293	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4386	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3954	331.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2567	2567	A	426	A	361	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	446	folP	852	852	100.0	folP.l6.c4.ctg.1	1989	66.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1269	1271	AGC	102;103;103	A;G;C,G	86;89;89,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	850	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3870	65.5	1	SNP	p	S91F	0	.	.	271	273	TCC	823	825	TCC	72;72;72	T;C,T;C	65;66,1;66	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	850	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3870	65.5	1	SNP	p	D95G	0	.	.	283	285	GAC	835	837	GAC	69;69;69	G;A;C	62;59;61	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	850	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3870	65.5	1	SNP	p	D95N	0	.	.	283	285	GAC	835	837	GAC	69;69;69	G;A;C	62;59;61	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	406	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1677	71.4	0	.	p	.	0	A39T	NONSYN	115	117	GCC	547	549	ACC	109;109;109	A;C;C	88;92;91	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	406	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1677	71.4	0	.	p	.	0	R44H	NONSYN	130	132	CGC	562	564	CAC	110;109;110	C;A;C	92;88;91	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	406	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1677	71.4	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	745	747	CAC	118;117;117	C,T;A;C	102,1;104;104	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	406	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1677	71.4	1	SNP	p	G45D	0	.	.	133	135	GGC	565	567	GGC	110;110;111	G;G;C	92;90;89	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	260	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1323	58.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	930	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3279	84.9	1	SNP	p	D86N	0	.	.	256	258	GAC	742	744	GAC	105;105;106	G;A;C	86;86;87	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	930	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3279	84.9	1	SNP	p	S87I	0	.	.	259	261	AGT	745	747	AGT	106;107;106	A;G;T	83;87;86	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	930	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3279	84.9	1	SNP	p	S87W	0	.	.	259	261	AGT	745	747	AGT	106;107;106	A;G;T	83;87;86	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	930	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3279	84.9	1	SNP	p	S87R	0	.	.	259	261	AGT	745	747	AGT	106;107;106	A;G;T	83;87;86	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	930	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3279	84.9	1	SNP	p	S88P	0	.	.	262	264	TCC	748	750	TCC	106;106;106	T;C;C	83;88;86	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	806	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3143	76.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1753	1755	GGC	102;102;102	G;G;C,A	84;84;82,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	718	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2945	72.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1510	1512	GCA	95;95;96	G,A;C;A,T	77,1;84;86,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	718	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2945	72.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1513	1515	ATC	95;96;96	A;T;C	81;79;83	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	718	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2945	72.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1525	1527	GTG	96;96;98	G;T;G,C	85;82;81,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	718	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2945	72.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1525	1527	GTG	96;96;98	G;T;G,C	85;82;81,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	718	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2945	72.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2029	2031	ACC	96;96;95	A,C;C,A;C	77,1;76,1;77	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	718	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2945	72.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2083	2085	GCG	81;81;81	G;C;G	70;59;64	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	718	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2945	72.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2083	2085	GCG	81;81;81	G;C;G	70;59;64	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	718	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2945	72.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2206	2208	GGC	91;91;92	G,C;G;C,T	75,1;76;77,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	718	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2945	72.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2215	2217	GGC	92;89;89	G;G;C,T,G,A	76;78;72,1,1,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	718	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2945	72.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2233	2235	CCG	87;87;87	C;C;G	70;76;72	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	886	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3483	76.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1778	1780	CTG	78;78;78	C;T;G	61;60;59	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	508	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2180	69.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	728	728	C	79	C,T	67,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	472	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1898	73.6	0	.	p	.	0	E48G	NONSYN	142	144	GAA	684	686	GGA	104;103;101	G;G;A	87;86;84	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	472	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1898	73.6	0	.	p	.	0	G50N	NONSYN	148	150	GGC	690	692	AAC	101;102;102	A;A;C	86;86;86	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	472	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1898	73.6	0	.	p	.	0	F135L	NONSYN	403	405	TTT	945	947	CTT	89;89;88	C;T;T	75;75;76	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	472	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1898	73.6	0	.	p	.	0	R143G	NONSYN	427	429	AGA	969	971	GGA	82;82;82	G,A,C;G;A	70,1,1;73;72	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	472	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1898	73.6	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1053	1055	GGT	85;85;84	G;G;T	67;68;67	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	472	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1898	73.6	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1107	1109	AGC	93;92;93	A,G;G,A;C	78,1;79,1;79	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	472	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1898	73.6	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1173	1173	T	89	T	73	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	472	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1898	73.6	1	SNP	p	G120K	0	.	.	358	360	GGT	900	902	GGT	94;94;94	G;G;T	80;80;79	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	472	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1898	73.6	1	SNP	p	A121D	0	.	.	361	363	GCC	903	905	GCC	94;93;94	G;C;C	80;78;80	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	472	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1898	73.6	1	SNP	p	A121N	0	.	.	361	363	GCC	903	905	GCC	94;93;94	G;C;C	80;78;80	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1734	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5199	99.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2189	2191	AAT	105;104;103	A;A;T	90;90;87	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	282	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1438	58.7	1	SNP	p	V57M	1	.	.	169	171	ATG	672	674	ATG	106;106;106	A;T,A;G	92;91,1;91	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
